APC and colorectal carcinoma: There is evidence that APC mutants have been associated with resistance against fluoropyrimidines such as capecitabine in CRC cell lines.32 The aforementioned APC mutation could therefore point toward a secondary capecitabine resistance development that may necessitate a therapy change.